Manager TitleAgeSince
Corporate Secretary 60 2019-08-07
Director TitleAgeSince
Director/Board Member 49 2020-04-20
Director/Board Member 60 2019-06-06
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+1.23%+0.35%+51.62%+87.98% 55.27B
+5.09%+6.24%+63.15%+62.06% 54.15B
+0.25%+0.55%-19.67%-15.22% 23.22B
+0.72%-0.05%+3.84%+409.54% 23.11B
-0.51%+5.52%+30.72%-3.77% 20.33B
-0.37%+0.71%+31.36%-31.61% 17.91B
-0.77%+6.29%+33.32%+547.87% 15.76B
-2.54%-8.73%+164.11%+289.45% 15B
+1.22%-0.05%+22.58%+182.63% 13.82B
Average +0.42%+0.71%+42.34%+169.88% 26.51B
Weighted average by Cap. +1.31%+2.77%+43.55%+134.94%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-